Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial

C. Mariotti, A. Solari, D. Torta, L. Marano, C. Fiorentini, Stefano Di Donato

Research output: Contribution to journalArticlepeer-review

Abstract

The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia. They found significant reductions of interventricular septal thickness and left ventricular mass in the idebenone group vs the placebo group, with no improvement in other heart ultrasound measures or neurologic condition. The absolute cardiac changes were modest, but the findings suggest that larger trials should assess whether idebenone reduces ventricular hypertrophy in patients with Friedreich ataxia.

Original languageEnglish
Pages (from-to)1676-1679
Number of pages4
JournalNeurology
Volume60
Issue number10
Publication statusPublished - May 27 2003

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial'. Together they form a unique fingerprint.

Cite this